Lowe Brockenbrough & Co. Inc. raised its stake in Pfizer, Inc. (NYSE:PFE) by 8.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,684 shares of the biopharmaceutical company’s stock after acquiring an additional 1,686 shares during the period. Lowe Brockenbrough & Co. Inc.’s holdings in Pfizer were worth $708,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Peachtree Investment Advisors Inc. increased its holdings in Pfizer by 1.3% in the 1st quarter. Peachtree Investment Advisors Inc. now owns 7,516 shares of the biopharmaceutical company’s stock valued at $257,000 after acquiring an additional 100 shares during the last quarter. Atlas Brown Inc. increased its holdings in Pfizer by 13.1% in the 1st quarter. Atlas Brown Inc. now owns 35,471 shares of the biopharmaceutical company’s stock valued at $1,213,000 after acquiring an additional 4,096 shares during the last quarter. Pure Financial Advisors Inc. increased its holdings in Pfizer by 0.4% in the 1st quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock valued at $756,000 after acquiring an additional 84 shares during the last quarter. Manning & Napier Advisors LLC increased its holdings in Pfizer by 5.2% in the 1st quarter. Manning & Napier Advisors LLC now owns 719,433 shares of the biopharmaceutical company’s stock valued at $24,610,000 after acquiring an additional 35,433 shares during the last quarter. Finally, Fulton Bank N.A. increased its holdings in Pfizer by 4.6% in the 1st quarter. Fulton Bank N.A. now owns 44,359 shares of the biopharmaceutical company’s stock valued at $1,518,000 after acquiring an additional 1,949 shares during the last quarter. Institutional investors own 69.09% of the company’s stock.

Pfizer, Inc. (PFE) traded down 0.693% during midday trading on Wednesday, reaching $35.125. 8,776,046 shares of the company’s stock traded hands. The firm’s 50-day moving average is $33.38 and its 200-day moving average is $33.49. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.43. The company has a market capitalization of $208.90 billion, a price-to-earnings ratio of 25.695 and a beta of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the business earned $0.64 earnings per share. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. Analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 1st. Shareholders of record on Friday, August 4th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 94.12%.

In other Pfizer news, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at $19,730,812. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 426,291 shares of company stock valued at $14,475,911. Company insiders own 0.06% of the company’s stock.

A number of analysts have issued reports on the stock. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, August 2nd. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a report on Wednesday. Berenberg Bank set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, August 1st. Morgan Stanley restated a “neutral” rating and issued a $35.00 target price (down from $38.00) on shares of Pfizer in a report on Monday, June 12th. Finally, Citigroup Inc. downgraded shares of Pfizer from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $37.72.

TRADEMARK VIOLATION WARNING: “Lowe Brockenbrough & Co. Inc. Increases Holdings in Pfizer, Inc. (PFE)” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/13/lowe-brockenbrough-co-inc-increases-holdings-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.